Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML

For more visit ResearchToPractice.com/5MJCMDSAML
Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately 20 percent of all hematologic cancer and related hemopathies diagnosed on an annual basis. Emerging and continuing clinical research has resulted in an increased understanding of the heterogeneous nature of these diseases and in the availability of novel treatment strategies and options. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in AML and MDS. To bridge the gap between research and patient care, this CME activity will deliver a serial review of recent key presentations and publications and expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for AML and MDS.

LEARNING OBJECTIVE

• Evaluate the Phase II study results of single-agent clofarabine for elderly patients with AML.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Hagop M Kantarjian, MD
Chairman and Professor, Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paid Research: Bristol-Myers Squibb Company, Genzyme Corporation, Novartis Pharmaceuticals Corporation.

Gail J Roboz, MD
Associate Professor of Medicine
Director, Leukemia Program
Weill Medical College of Cornell University
NewYork-Presbyterian Hospital
New York, New York


Steven D Gore, MD
Professor of Oncology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Consulting Agreement and Stock Ownership: Celgene Corporation; Paid Research: Celgene Corporation, Johnson & Johnson Pharmaceuticals.

EDITOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Merck and Company Inc, Millennium Pharmaceuticals Inc, Monogram Biosciences, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS

— The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This program is supported by an educational grant from Celgene Corporation.

Last review date: November 2009
Expiration date: November 2010
Inside this issue: Four interesting AML nuggets:

1. **A Phase II study** evaluating clofarabine in 112 older patients (median age 71) with AML and one or more adverse prognostic factors. Treatment was “well tolerated” and resulted in 38% CRs.

2. **A Phase II study** of the hypomethylating agent decitabine in 55 older patients (median age 74) with AML. Morphologic CR was observed in 24%; febrile neutropenia was observed in 24%.

3. **A literature review** suggesting that assays for NPM1mut and FLT3 ITDneg could be the new ER and HER2 of AML. (Ok, maybe that is an overstatement, but these are highly prognostic and predictive.)

4. **A retrospective analysis** demonstrating roughly similar results with allogeneic hematopoietic stem cell transplant in patients with AML over and under age 65.

**Editor’s comment: Who should treat patients with AML?**

Mike Schwartz, a Memorial-trained medical oncologist practicing in Miami Beach, is one of several dozen “master clinicians” across the country who have assisted us with our CME programs. Mike’s most recent contribution was helping us plan an upcoming **Satellite Symposium** that we will host in New Orleans on Friday night, December 4, preceding the ASH annual meeting.

Dr Schwartz will join four other community-based physicians as they present challenging cases of AML, MDS, CML, and myeloma from their practices to our all-star faculty. In addition to discussing these carefully selected patients, we will also reveal the results of our recent **national Patterns of Care survey** of US-based oncologists, specifically focusing on the management of the cases being presented at the meeting.

One interesting survey question that we will discuss live is “Do you treat some or most patients with AML or do you generally refer them to a tertiary center?” To my mild surprise, more than two thirds of the survey respondents generally manage these patients themselves, and that includes Mike, who will present a 59-year-old woman recently diagnosed with AML.
Our prior surveys have documented that oncologists in practice see about as many cases of breast cancer a year as breast cancer investigators, but AML is a complicated disease that occurs at less than one tenth the frequency.

Of course there is more than science required in these intense situations, as evidenced by Mike’s patient, an Asian woman, who asked if she could take traditional therapeutic herbs during chemo (Mike said “No,” as did 79 percent of the oncologists surveyed).

Certainly physicians who offer patients a local means to receive treatment for a very scary disease must do their best to keep up with the gradual but definite progress in AML. In New Orleans, we’ll see what our faculty has to say about Mike’s patient and whether they think she, like many others, can be effectively managed in the community. From my standpoint, this woman is fortunate to be receiving care from one of the many, many extraordinary clinicians working outside of academic medicine.

Next up on 5-Minute Journal Club: The final four papers highlighted in our series along with results from our Patterns of Care study documenting oncologists’ management of MDS.

Neil Love, MD
Research To Practice
Miami, Florida
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML

Presentations discussed in this issue:


Kantarjian M et al. Classic II: Updated remission duration and survival results of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia and at least one unfavorable baseline prognostic factor. *Haematologica* 2009;94; [Abstract 0835].

Slides from a presentation at ASH 2008, transcribed comments from a recent presentation by Hagop M Kantarjian, MD (10/17/09) and recent interviews with Gail J Roboz, MD (10/6/09) and Steven D Gore, MD (10/8/09) below

---

**A Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit: CLO24300606/CLASSIC II**

---

**Erba HP et al.**

*Blood* 2008;112: Abstract 558
Introduction

- Older patients with AML have inferior treatment outcomes due to increased incidence of patient- and disease-related adverse risk factors:
  - High treatment-related mortality rate
  - Lower CR rates and short remission duration
  - Inadequate outcomes with cytarabine and anthracycline induction therapy for patients with unfavorable prognostic risk factors
- **Current study objectives:**
  - Primary: Determine the overall remission rate (ORR) with clofarabine in patients ≥60 years old with untreated AML and ≥1 adverse prognostic factor
  - Secondary: 30-day mortality; disease-free survival (DFS); remission duration; overall survival (OS); safety and tolerability


---

Phase II Study of Clofarabine in Older Patients with AML

<table>
<thead>
<tr>
<th>Eligibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Untreated AML, ≥60 years old, ≥1 unfavorable prognostic factor (≥70 years old; PS=2; antecedent hematologic disorder (AHD); intermediate/unsatisfactory risk karyotype)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment (n=112)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Induction: Clofarabine, 30 mg/m² days 1-5</td>
</tr>
<tr>
<td>• Re-induction/consolidation: Clofarabine, 20 mg/m² days 1-5 (Maximum number of cycles = 6)</td>
</tr>
</tbody>
</table>

## Results: Response by Independent Review Panel (IRRP) (n=112)

<table>
<thead>
<tr>
<th>Response</th>
<th>N</th>
<th>Response Rate, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td>51</td>
<td>46% (36, 55)</td>
</tr>
<tr>
<td>Complete remission with incomplete platelet recovery (CRp)</td>
<td>42</td>
<td>38% (29, 47)</td>
</tr>
<tr>
<td>Partial remission</td>
<td>9</td>
<td>8% (Not reported)</td>
</tr>
<tr>
<td>Remissions (CR + CRp) after cycle 1 (induction)</td>
<td>4</td>
<td>4% (Not reported)</td>
</tr>
<tr>
<td>Remissions (CR + CRp) after cycle 2 (re-induction)</td>
<td>38</td>
<td>8% (Not reported)</td>
</tr>
<tr>
<td>Remissions (CR + CRp) after cycle 3 (re-induction)</td>
<td>13</td>
<td>25% (Not reported)</td>
</tr>
</tbody>
</table>

Median time to ORR = 5.1 weeks
Median time to peripheral blood blast clearance: 5 days
Median duration of response for CR/CRp = 56 weeks*

*Updated results, Kantarjian M et al. Haematologica 2009;94[52];336. Abstract 0835

## Results: Survival

<table>
<thead>
<tr>
<th>Survival</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Median DFS (CR/CRp)</td>
<td>37 weeks</td>
</tr>
<tr>
<td>Median OS</td>
<td></td>
</tr>
<tr>
<td>All patients (n=112)</td>
<td>41 weeks</td>
</tr>
<tr>
<td>Patients with CR/CRp</td>
<td>59 weeks</td>
</tr>
<tr>
<td>Patients with CR</td>
<td>72 weeks</td>
</tr>
<tr>
<td>30-day mortality</td>
<td></td>
</tr>
<tr>
<td>All patients (n=112)</td>
<td>9.8%</td>
</tr>
<tr>
<td>Patients &lt; 70 years old</td>
<td>4.7%</td>
</tr>
<tr>
<td>Patients ≥ 70 years old</td>
<td>13.0%</td>
</tr>
</tbody>
</table>

Source: Kantarjian M et al. Haematologica 2009;94[52];336. Abstract 0835
## Drug-Related Adverse Events in ≥10% of Patients

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Number of Patients</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades</td>
<td>Grade 3</td>
<td>Grade 4/5</td>
</tr>
<tr>
<td>Nausea</td>
<td>69</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>49</td>
<td>46</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>43</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>38</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>34</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>20</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>17</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Anorexia</td>
<td>15</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Mucosal inflammation</td>
<td>13</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>


## Conclusions

- Single-agent clofarabine is an active agent with acceptable toxicity in a well-defined population of older patients with AML who do not typically benefit from standard induction chemotherapy
  - The response rate was not affected by adverse risk factors such as age ≥70 years, PS 2, AHD and unfavorable blast karyotype
  - DFS and OS compare favorably to historical experience with other regimens
    - Median DFS = 37 weeks; median OS = 41 weeks; all-cause 30-day mortality = 9.8%*
    - Complete remissions appear to be durable (median DOR = 56 weeks)
- A Phase III study of clofarabine with cytarabine versus cytarabine alone is currently open for enrollment: NCT00317642, CLASSIC I


*Updated results, Kantarjian M et al. Haematologica 2009;94[S2];336. Abstract 0835
DR KANTARJIAN: In older patients, we are hoping for something good with clofarabine, an adenosine analog like CDA and fludarabine, but it’s completely different in the sense that it doesn’t work in lymphoid tumors, except for pediatric leukemias, but it has a major effect in acute myeloid leukemia (AML) and in myelodysplastic syndromes.

We developed this Phase II study three years ago and enrolled older patients with AML with adverse features, and we demonstrated that the drug is associated with a response rate of 40 percent that persists across combinations of adverse factors, with a low mortality of under 10 percent at four weeks. What we see in this study is that once the patients have a response, it is durable beyond a year, and the median survival is approximately nine months with the one-year survival rate at approximately 45 percent. The data are encouraging, and we are proceeding with randomized trials with this drug.

DR ROBOZ: This is an interesting paper for clinicians because fairly few drugs out there have a meaningful complete remission rate in AML. Physicians need to be aware of these data, because clofarabine is a single-agent drug with a relatively high complete remission rate and a favorable toxicity profile. Currently, a randomized cooperative group trial of clofarabine with cytarabine versus cytarabine alone is being conducted and physicians need to try to accrue patients to it.
**DR GORE:** In this study, 112 elderly patients with AML received single-agent clofarabine, resulting in an overall response rate of 46 percent, with complete responses of 38 percent. There is no question that this drug warrants further investigation.

*Dr Kantarjian is Chairman and Professor of the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.*

*Dr Roboz is Associate Professor of Medicine and Director of the Leukemia Program at Weill Medical College of Cornell University at NewYork-Presbyterian Hospital in New York, New York.*

*Dr Gore is Professor of Oncology at Johns Hopkins University in Baltimore, Maryland.*